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Abstract
 
We report that stromal cell–derived factor (SDF)-1 has the remarkable capacity to induce sus-
tained signaling through CXC chemokine receptor 4 (CXCR4). In contrast to other chemo-
kines, such as monocyte chemotactic protein 1 (CC chemokine receptor 2 [CCR2]), macro-
 
phage inflammatory protein 1
 
b
 
 (CCR5), liver and activation-regulated chemokine (LARC
[CCR6]), Epstein-Barr virus–induced molecule 1 ligand chemokine (ELC [CCR7]), and IP10
(CXCR3), SDF-1 stimulates the prolonged activation of protein kinase B and extracellular sig-
nal–regulated kinase (ERK)-2. Activation of protein kinase B is reversed by displacement of
SDF-1 from CXCR4 or inhibition of phosphatidylinositol 3-kinase. Although increasing con-
centrations of SDF-1 enhance CXCR4 internalization, kinase activation is prolonged. In addi-
tion, restimulation yields 
 
.
 
60% of initial protein kinase B activity, indicating that the remain-
ing receptors are not desensitized. Furthermore, activation is prolonged by inhibiting SDF-1
degradation. The sustained activation of cell survival and mitogenic pathways may account for
the unique role of SDF-1 and CXCR4 in embryogenesis and lymphopoiesis.
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Introduction
 
Chemokines constitute the largest family of cytokines, with
more than
 
 
 
50 distinct members acting on at least 16 differ-
ent receptors (1, 2). Initially, chemokines were character-
ized as inflammatory mediators. It is now becoming clear
 
that the chemokine system is involved in many physiolog-
ical and pathological processes, such as inflammation, tu-
morigenesis, hematopoiesis, development, embryogenesis,
and HIV infection (1, 3–5). All chemokine receptors be-
long to the same class of seven transmembrane domain re-
 
ceptors and are associated with heterotrimeric G
 
i
 
 proteins.
Despite their structural similarity and the coupling to the
same type of G protein, they can activate specific signal
transduction pathways leading to diverse responses. How-
ever, the association of the receptors with distinct signal
transduction pathways is poorly understood.
Expansion of blood-derived T lymphocytes in the pres-
ence of IL-2 induces the expression of several chemokine
receptors that can mediate various functional responses (6).
These cells can therefore be used for the study of molecular
mechanisms of signal transduction initiated by chemokine
receptors. Many chemokines bind to more than one recep-
tor, and the receptors generally bind more than one
chemokine (1). Stromal cell–derived factor (SDF)
 
1
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contrast, is the unique ligand for CXC chemokine receptor
4 (CXCR4). Targeted gene disruption of SDF-1 or
CXCR4 in mice is lethal, and morphological analysis of
embryos revealed similar phenotypes in both deficiencies,
suggesting that SDF-1 interacts exclusively with CXCR4
and vice versa (7–9). The experiments further demon-
strated that SDF-1 is not a classical inflammatory chemo-
kine but is essential for normal embryogenesis since or-
ganogenesis, lymphopoiesis, vascularization, and the
development of the central nervous system were impaired
in the knockout animals. CXCR4 acts as coreceptor for in-
fection with X4-tropic HIV strains (10). SDF-1 protects
against HIV-1 infection by competing with gp120 for
binding to CXCR4 and by downregulation of the receptor
from the cell surface (11).
Signal transduction by chemokine receptors leads to the
activation of G proteins and phospholipase C and the ele-
vation of cytosolic free calcium (2). We and others have
shown that stimulation of chemokine receptors results in
the transient activation of the mitogen-activated protein
(MAP) kinase extracellular signal–regulated kinase (ERK)-2
(12–14). Activation of ERK-2 is Ras dependent, and
prolonged activation causes its nuclear translocation and
activation of transcription (15). Recently, it was shown that
chemokines stimulate phosphatidylinositol 3-kinase (PI
3-kinase) leading to the formation of phosphatidyl 3,4,5,-
triphosphate (PIP
 
3
 
; 16, 17) and the activation of protein ki-
nase B (also termed Akt or RAC-PK) (18). Attenuation of
PI 3-kinase with the specific inhibitor wortmannin (19) ab-
rogates protein kinase B activation (20). Thus, PI 3-kinase
activity is necessary and sufficient to stimulate protein ki-
nase B (21). Activation of protein kinase B is accomplished
by binding of its pleckstrin homology (PH) domain to
3-phosphoinositides and the phosphorylation of two critical
residues (Thr
 
308
 
 and Ser
 
473
 
) by phosphoinositide-dependent
kinase(s) (22). Activated protein kinase B promotes cell sur-
vival by phosphorylating and inactivating several apoptosis-
mediating proteins such as BAD (23), caspase-9 (24), and a
forkhead transcription factor (25, 26).
In this study, we demonstrate that SDF-1 has the re-
markable capacity to promote prolonged signaling through
CXCR4 in T lymphocytes. Although other chemokines
induce a transient activation of protein kinase B and ERK-2,
SDF-1 stimulates a markedly enhanced and prolonged acti-
vation of the two signal transduction pathways. Sustained
protein kinase B activation is shown to depend on active
CXCR4 persisting at the cell surface, interaction with G
 
i
 
proteins, and the continuous activation of PI 3-kinase. Fur-
thermore, we found that the subsistence of sustained kinase
activation is more prominent in the presence of inhibitors
of dipeptidyl peptidase CD26 and is regulated by the inter-
nalization of CXCR4.
 
Materials and Methods
 
Materials.
 
Cell culture media and supplements were obtained
from GIBCO BRL. Monocyte chemotactic protein (MCP)-1,
macrophage inflammatory protein (MIP)-1
 
b
 
, liver and activa-
 
tion-regulated chemokine (LARC), EBV-induced molecule 1
ligand chemokine (ELC), IP10, SDF-1, and SDF-1P2G (27)
were chemically synthesized. Human recombinant IL-2 was pro-
vided by Dr. A. Lanzavecchia (Basel Institute of Immunology,
Basel, Switzerland). Crosstide (28) and 17-hydroxywortmannin
(29) were gifts from Dr. B.A. Hemmings (Friedrich Miescher-
Institute, Basel, Switzerland) and Dr. T. Payne (Novartis, Basel,
Switzerland), respectively.
 
Antibodies.
 
Alkaline phosphatase– and horseradish peroxi-
dase–conjugated goat anti–rabbit or anti–mouse IgG were from
Bio-Rad Laboratories; anti–ERK-2 was from Santa Cruz Bio-
technology, Inc., and anti-AKT/protein kinase B and phospho-
AKT/protein kinase B (Ser
 
473
 
) antibodies were from New En-
gland Biolabs, Inc. RPE-conjugated goat anti–mouse IgG was
from Dako; anti–MAP kinase (activated, diphosphorylated ERK-1
and ERK-2) and mouse isotype controls were from Sigma-
Aldrich. The murine mAb to CXCR4 (6H8, IgG
 
1
 
) was provided
by Dr. Fernando Arenzana-Seisdedos (Pasteur Institute, Paris,
France). The anti-CXCR4 mAb 12G5 (IgG
 
2a
 
) was a gift from
Dr. J. Hoxie (University of Pennsylvania Medical Center, Phila-
delphia, PA), and the anti-CCR5 mAb 5C7 (IgG
 
2a
 
) was provided
by LeukoSite, Inc. (Cambridge, MA).
 
Cell Preparation and Culture.
 
Human PBMCs were isolated
from donor blood (Swiss Red Cross Laboratory) by Ficoll-Paque
gradient centrifugation. PBLs were obtained by removing mono-
cytes by adherence or by Percoll gradient centrifugation (30).
Lymphocytes were cultured in RPMI supplemented with 1%
glutamine, nonessential amino acids, sodium pyruvate and kana-
mycin, 50
 
 
 
m
 
M 2-ME, 5% human serum (Swiss Red Cross Labo-
ratory), and human recombinant IL-2 (200 U/ml). The cell den-
sity was kept between 1 and 3 
 
3
 
 10
 
6
 
 cells/ml by diluting with
medium containing IL-2. After 6 d, 
 
.
 
90% of the cells were
CD3
 
1
 
 and they were used after 9–12 d of IL-2 treatment (6).
 
Cell Stimulation.
 
If not stated otherwise, IL-2–expanded T
cells were serum-starved overnight in medium supplemented
with 200 U/ml IL-2. The cells were washed twice and resus-
pended in HBSS containing 20 mM Hepes, pH 7.4 (2 
 
3
 
 10
 
7
 
cells/ml). Aliquots of 2 
 
3
 
 10
 
6
 
 cells for immunoblotting and 6 
 
3
 
10
 
6
 
 cells for immunoprecipitation were incubated for 10 min at
37
 
8
 
C and then stimulated with the appropriate agonist. For
Western blot analysis, the incubations were terminated by the ad-
dition of TCA. The incubation of samples for immunoprecipita-
tion was stopped by the addition of double concentrated ice-cold
lysis buffer (50 mM Tris-Cl, pH 7.5, 1% NP-40, 120 mM NaCl,
1 mM EDTA, 25 mM NaF, 40 mM 
 
b
 
-glycerophosphate, 0.1
mM sodium vanadate, 0.5 mM PMSF, 1 mM benzamidine, and
1 
 
m
 
M Microcystin-LR; Alexis Corp.), and the samples were im-
mediately frozen in liquid nitrogen.
 
Immunoprecipitation and In Vitro Kinase Assay.
 
Frozen lysates
were thawed on ice, centrifuged for 10 min at 12,000 
 
g
 
 at 4
 
8
 
C,
and precleared with protein A–Sepharose. Protein kinase B was
immunoprecipitated from 5 
 
3 
 
10
 
6
 
 cell equivalents for 3 h at 4
 
8
 
C
with anti-AKT/protein kinase B antibody. Immunoprecipitates
were washed once with lysis buffer containing 0.5 M NaCl, once
with lysis buffer, and twice with kinase buffer (50 mM Tris-Cl,
pH 7.5, 1 mM dithiothreitol, 0.5 mM PMSF, 1 mM benzami-
dine, and 1 
 
m
 
M Microcystin-LR). Kinase assays were performed
for 2 h as described previously using Crosstide (GRPRTSS-
FAEG) as substrate (28). The immunoprecipitated protein kinase
B content was analyzed by Western blotting.
 
Western Blot Analysis.
 
Immunoprecipitated or total protein
samples were resolved on 11% SDS-PAGE and transferred to Im-
mobilon-P membranes. The membranes were incubated with the 
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corresponding antibody overnight. Enhanced chemiluminescence
was used for detection of horseradish peroxidase–conjugated sec-
ondary antibodies. Membranes were subsequently stripped using
0.2 M NaOH for 5 min, washed, and reprobed with the appro-
priate antibodies. For ERK-2 detection, alkaline phosphatase–
conjugated antibodies were used.
 
Phosphoinositide Determination.
 
Approximately 1.2 
 
3 
 
10
 
8
 
 se-
rum-starved, IL-2–expanded T cells were loaded with 0.3 mCi/
ml [
 
32
 
P]orthophosphate (Amersham Pharmacia Biotech) in 10 ml
phosphate-free RPMI supplemented with 20 mM Hepes, pH
7.3, for 2 h at 37
 
8
 
C. The cells were washed twice in RPMI sup-
plemented with 20 mM Hepes, pH 7.3, and resuspended at 6.5 
 
3
 
10
 
7
 
 cells/ml in the same medium. Aliquots of 150 
 
m
 
l were treated
with chemokine, antagonist, or wortmannin in a final volume of
170 
 
m
 
l. Reactions were quenched by the addition of 640 
 
m
 
l
CH
 
3
 
Cl/MeOH (1:2), and lipids extracted were analyzed by
HPLC as described (31).
 
Calcium.
 
The intracellular free calcium concentration was
determined as described previously (32).
 
Flow Cytometry.
 
PBMCs (5 
 
3
 
 10
 
6
 
/ml) or serum-starved IL-2–
expanded T cells (2 
 
3
 
 10
 
7
 
/ml) were incubated at 37
 
8
 
C in RPMI
supplemented with 10% FCS in the presence or absence of SDF-1
for various times. Before staining with antireceptor antibodies, cell-
bound chemokine was removed by an acidic glycine wash (11).
Single-color analysis was performed with mouse mAbs against
CCR5, CXCR4, or isotype-matched control IgG, followed by
PE-conjugated goat anti–mouse IgG. For two-color analysis, the
cells were first stained for the chemokine receptor, then saturated
with 10% mouse serum before addition of FITC-conjugated
mouse anti-CD3 antibodies. Cell-associated fluorescence was ana-
lyzed with a FACScan™ flow cytometer (Becton Dickinson).
 
Results
 
SDF-1 Stimulates Prolonged Protein Kinase B and ERK-2
Activation.
 
Human T cells cultured for 9–12 d in the pres-
ence of IL-2 exhibit similar chemotactic responsiveness to
several CXC and CC chemokines (33) and were therefore
used to compare the signaling properties of different
chemokine receptors. Under the experimental conditions
used, each chemokine binds only to one receptor and in-
duces receptor-specific signal transduction (33). SDF-1
binds to CXCR4 (32), MCP-1 to CCR2 (34), MIP-1
 
b
 
 to
CCR5 (35, 36), LARC to CCR6 (37), ELC to CCR7
(38), and IP10 to CXCR3 (39). As downstream effector,
we investigated the activation of protein kinase B. To min-
imize basal activity of the kinase, the cells were starved
overnight before treatment with the chemokines. Activa-
tion of protein kinase B correlates with its phosphorylation
at two residues, Thr
 
308
 
 and Ser
 
473
 
 (22). We used an anti-
body that reacts specifically with the phosphorylated Ser
 
473
 
located at the COOH terminus to determine chemokine-
stimulated activation of protein kinase B. Fig. 1 A (left)
shows a typical Western blot of whole cell lysates separated
by SDS-PAGE. Except for the CCR6 ligand, LARC, all
chemokines induced a rapid phosphorylation of protein ki-
nase B. MCP-1, MIP-1
 
b
 
, and IP10 stimulated a transient
activation that peaked at 
 
z
 
1 min and ceased within 2–5
min. The response to ELC was somewhat more protracted,
lasting for up to 10–20 min (depending on the cell batch
used). In contrast, SDF-1 stimulated a strong and markedly
 
prolonged activation of protein kinase B that was detect-
able for up to 90 min. Total protein kinase B was deter-
mined by stripping and reprobing the blots with an antibody
reacting with both the phosphorylated and nonphosphory-
lated enzyme (Fig. 1 A, right). Enzyme activity was mea-
sured in antiphospho-Ser
 
473
 
 immunoprecipitates using
Crosstide as specific peptide substrate (28). The results con-
firmed that SDF-1 stimulates a protracted activation of pro-
tein kinase B that persists for at least 40 min (Fig. 1 B).
Maximum kinase activity was consistently observed 
 
z
 
1
min after stimulation, whereas the extent varied between
cells from different donors (10–20-fold activation). On
Western blots, the strong initial stimulation appears less
pronounced due to the poor linearity of the enhanced
chemiluminescence detection method.
We next compared protein kinase B activity in immuno-
precipitates obtained from cells stimulated with various
chemokines (Fig. 1 C). MIP-1
 
b
 
– and MCP-1–induced ki-
nase activity returned to baseline values within 5 min even
at chemokine concentrations as high as 1 
 
m
 
M. Consistent
with the Western blot analysis, ELC and SDF-1–elicited
enzyme activity was more protracted. However, the most
pronounced activation was again obtained with SDF-1.
The stimulatory capacity of SDF-1 was not restricted to IL-
2–expanded T cells. Similar levels of protein kinase B acti-
vation were obtained with freshly isolated CXCR4
 
+
 
 PBLs,
the human T cell lines CEMx174 and J.Jahn, the mono-
cytic cell line GM-1, and HeLa cells. In all cases, SDF-1 in-
duced a strong protein kinase B activation that lasted for at
least 40 min. Pretreatment of the cells with 
 
Bordetella pertus-
sis
 
 toxin abrogated the response to SDF-1, indicating that
protein kinase B activation depends on coupling of
CXCR4 to a heterotrimeric G
 
i
 
 protein.
Regulated on activation, normal T cell expressed and se-
creted protein (RANTES) is a potent activator of T cells
and binds to two chemokine receptors, CCR1 and CCR5
(6, 40). Stimulation of IL-2–expanded T cells with RANTES
resulted in a protein kinase B activation that was compara-
ble to that induced by MCP-1 or MIP-1
 
b
 
, suggesting that
CCR1 possesses similar stimulatory capacity as other recep-
tors for inflammatory chemokine.
The prolonged activation of protein kinase B elicited by
SDF-1 was unexpected and appeared to be a distinctive
characteristic of the G
 
i
 
 protein–coupled receptor CXCR4.
Therefore, we investigated whether SDF-1 causes pro-
tracted activation of other intracellular signal transduction
pathways. Previous studies demonstrated that the MAP ki-
nase kinase cascade leading to the activation of ERK-2 is
regulated independently of protein kinase B (28), and
chemokines were shown to stimulate ERK-2 activity in
Jurkat cells (12). Using the same panel of chemokines, we
compared the activation of ERK-2 in T cells. Fig. 1 D rep-
resents a Western blot analysis of ERK-2 activation per-
formed with the same lysates as used in Fig. 1 A. Stimula-
tion of ERK-2 results in the retarded electrophoretic
mobility of the threonine- and tyrosine-phosphorylated
enzyme that is detected by a specific antibody reacting with
both resting and activated enzyme. Fig. 1 D shows that the 
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most prominent and long-lasting effect was again obtained
with SDF-1. With 100 nM SDF-1, phosphorylated ERK-2
was detectable for up to 90 min (see Fig. 4). The extent did
not vary significantly between cell batches. The overall re-
sponses resembled the pattern obtained for protein kinase B
stimulation. MCP-1, MIP-1
 
b
 
, and IP10 induced a tran-
sient activation of ERK-2, whereas the response to ELC
was more protracted. LARC, which did not affect protein
kinase B, showed a weak activation of ERK-2. Similar re-
sults were obtained when the blots were developed with a
specific antibody detecting diphosphorylated ERK-1 and
ERK-2.
Testing the chemokine concentration dependence of
protein kinase B and ERK-2 activation revealed expected
dose–response curves. Marginal activation of both kinases
was obtained with 1 nM of chemokine and maximum acti-
vation was obtained with 100 nM (see Fig. 4, and data not
shown). The finding is in good agreement with the re-
ported affinities of the chemokines for their respective re-
ceptors (33) and confirms previous observations obtained
with other chemokines (18).
 
Effect of the SDF-1 Antagonist SDF-1P2G on Protein Ki-
nase B Activation.
 
By substituting Pro
 
2
 
 with glycine in the
 
NH
 
2
 
 terminus of SDF-1 (K[P
 
®
 
G]VSLSYRC…) a potent
receptor antagonist, SDF-1P2G, is obtained that binds with
similar high affinity as SDF-1 to CXCR4, i.e., 9 nM com-
pared with 3–4 nM for SDF-1 (27). SDF-1P2G does not
induce signal transduction or receptor downregulation
even at 10 
 
m
 
M (not shown), and CD4
 
+
 
CXCR4
 
+
 
 cells are
only marginally protected against infection with X4-tropic
HIV strains (27). We used the antagonist to elucidate signal
transduction mechanisms that are responsible for the pro-
longed stimulatory capacity of CXCR4. Fig. 2 A demon-
strates that pretreatment of T cells with 10 
 
m
 
M SDF-1P2G
completely inhibits SDF-1–stimulated protein kinase B ac-
tivation. Moreover, SDF-1P2G did not induce activation
of protein kinase B (Fig. 2 A) or ERK-2 (not shown). To
test whether the antagonist can terminate protein kinase B
activation if added after SDF-1, the cells were first stimu-
lated with 100 nM SDF-1 for 5 or 10 min and then treated
with 10 
 
m
 
M SDF-1P2G for 5 min. Fig. 2 B shows that the
subsequent addition of SDF-1P2G leads to a rapid dephos-
phorylation of protein kinase B. Similar results were ob-
tained when protein kinase B activity was determined in
immunoprecipitates (Fig. 2 C). Stimulation with 100 nM
SDF-1 for 10 min resulted in a sixfold increase in protein
Figure 1. Chemokine-stimulated activation of protein kinase B and ERK-2 in T cells. (A) Activation of protein kinase B determined by Western blot
analysis. T cells were stimulated with 200 nM MCP-1, MIP-1b, LARC, ELC, IP10, or SDF-1 for the indicated times. Whole cell lysates were separated
on SDS-PAGE and activated protein kinase B was detected with an antibody reacting with phosphorylated Ser473 (pS47 3PKB, left). To confirm equal
loading of protein kinase B, blots reprobed with an antibody reacting with both activated and nonactivated protein kinase B (PKB, right). (B) Time
course of protein kinase B activation. Enzyme activity was determined in immunoprecipitates from lysates of cells stimulated with 100 nM SDF-1. Kinase
assays were performed in duplicate, and the results are presented as fold activation (mean values). (C) Comparison of protein kinase B activity in immu-
noprecipitates from cells stimulated for 1 or 5 min with 100 nM SDF-1, ELC, MCP-1, or MIP-1b. (D) Western blot analysis of ERK-2 activation. Cells
were stimulated with 200 nM MCP-1, MIP-1b, LARC, ELC, IP10, or SDF-1 for the indicated times and whole cells lysates were separated by SDS-
PAGE. Activated ERK-2 (pERK-2) migrates with a slower electrophoretic mobility than nonactivated ERK-2 (ERK-2). Representative results obtained
with cells from single donors are shown. Independent experiments with at least four more batches of cells from different donors gave similar results. 
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kinase B activity, whereas 10 
 
m
 
M SDF-1P2G had no ef-
fect. Pretreatment of the cells with SDF-1P2G fully inhib-
ited the stimulation by SDF-1. Furthermore, addition of
the antagonist after SDF-1 decreased protein kinase B ac-
tivity to basal levels within 5 min. Two main conclusions
can be drawn from these results: (a) continuous receptor–
ligand interaction is required for sustained protein kinase B
activation, and (b) CXCR4 must be expressed on the cell
surface to remain accessible for SDF-1P2G.
 
Effect of the PI 3-Kinase Inhibitor Wortmannin on Protein Ki-
nase B Activation.
 
The specific PI 3-kinase inhibitor wort-
mannin (19) is known to block receptor-mediated activa-
tion of protein kinase B (18, 20, 21). Fig. 3 A shows that
preincubation of IL-2–expanded T cells with 100 nM
Figure 2. Effect of the CXCR4 antagonist,
SDF-1P2G, on SDF-1–induced protein kinase B
activation. (A) T cells were pretreated with 10 mM
SDF-1P2G (P2G) or medium for 5 min and stimu-
lated with 100 nM SDF-1 for 10 min. (B) The cells
were stimulated with 100 nM SDF-1 for 5, 10, or
15 min. Where indicated, 10 mM SDF-1P2G
(P2G) was added 5 min before termination of the
stimulation. Activated (pSer47 3PKB) and total pro-
tein kinase B(PKB) were determined as in the leg-
end to Fig. 1 A. (C) Protein kinase B activity in im-
munoprecipitates. The cells were either treated
with medium (Cont), 100 nM SDF-1 (SDF-1), or
10 mM SDF-1P2G (P2G) for 10 min, or treated
with 10 mM SDF-1P2G for 5 min before stimula-
tion with 100 nM SDF-1 for 10 min (P2G . SDF-
1), or were stimulated with 100 nM SDF-1 and 5
min later treated with 10 mM SDF-1P2G for an ad-
ditional 5 min (SDF-1 . P2G). Results are ex-
pressed as in Fig. 1 C. Similar results were obtained
with cells from three different donors.
Figure 3. Effect of wortman-
nin on SDF-1–induced protein
kinase B activation and PIP3
production. (A) T cells were
pretreated with 100 nM wort-
mannin for 10 min and stimu-
lated with 100 nM SDF-1 for 10
min. (B) The cells were stimu-
lated with 100 nM SDF-1 for 1,
5, 10, and 15 min. Where indi-
cated, 100 nM wortmannin was
added 5 min before termination
of the stimulation. Activated
(pSer473PKB) and total protein
kinase B (PKB) were determined
as in the legend to Fig. 1 A. (C)
Protein kinase B activity in im-
munoprecipitates. The cells
were either treated with me-
dium (Cont), 100 nM SDF-1
(SDF-1), or 100 nM wortman-
nin (wort) for 10 min, or were
treated with 100 nM wortman-
nin for 10 min before stimula-
tion with 100 nM SDF-1 for 10
min (wort . SDF-1), or were
stimulated with 100 nM SDF-1
and 5 min later treated with 100
nM wortmannin for an addi-
tional 5 min (SDF-1 . wort).
Results are expressed as in Fig. 1
C. D. PIP3 formation in [32P]or-
thophosphate-loaded T cells.
The cells were either treated
with medium (Cont), 100 nM
SDF-1 (SDF-1 109), 100 nM wortmannin (wort), 10 µM SDF-1P2G (P2G) for 10 min or with 100 nM SDF-1 for 1 min (SDF-1 19), or were stimu-
lated with 100 nM SDF-1 and 5 min later treated with 100 nM wortmannin (SDF-1 . wort) or 10 mM SDF-1P2G (SDF-1 . P2G) for an additional
5 min. Lipids were extracted, deacylated, and glycerophosphoinositides were separated by HPLC (duplicate determinations). Results are representative
for at least three independent experiments.318 CXCR4-mediated Signal Transduction
wortmannin prevents SDF-1–mediated activation of pro-
tein kinase B. Furthermore, when wortmannin was added
5 or 10 min after stimulation of the cells with SDF-1, a
rapid dephosphorylation of Ser473 of protein kinase B was
observed (Fig. 3 B). Kinase activity measurements in im-
munoprecipitates prepared from wortmannin-treated cells
confirm the findings (Fig. 3 C). Preincubation of serum-
starved cells with 100 nM wortmannin abolished the basal
protein kinase B activity and attenuated the stimulation by
SDF-1. When wortmannin was added 10 min after treat-
ment of the cells with SDF-1, protein kinase B activity was
inhibited within 5 min, indicating that a continuous supply
of 3-phosphoinositides is necessary to maintain the elevated
protein kinase B activity. This conclusion was corroborated
by measurements of the PIP3 levels. As shown in Fig. 3 D,
SDF-1 stimulated a rapid accumulation of PIP3. A seven-
fold increase of the basal level was obtained within 1 min
that remained elevated three- to fourfold for at least 10
min. Treatment of the cells with 100 nM wortmannin de-
creased the basal content of PIP3, whereas 10 mM SDF-
1P2G had no effect. Both wortmannin and SDF-1P2G,
when added during the course of SDF-1–dependent PIP3
formation, rapidly reversed the activation of PI 3-kinase
and the levels of PIP3 returned to baseline values. These
findings confirm that phosphorylation of protein kinase B is
tightly coupled to the activation of PI 3-kinase and that
sustained PIP3 formation is critical for retaining protein ki-
nase B in the active state. In addition, the results demon-
strate that PI 3-kinase activation requires the continuous
interaction of SDF-1 with CXCR4.
Effect of the SDF-1 Concentration on Protein Kinase B and
ERK-2 Activation. The duration of protein kinase B acti-
vation was concentration dependent, lasting 5–10 min with
10 nM SDF-1 and up to 60–90 min with 1 mM SDF-1
(Fig. 4 A). However, consistent with a Kd of 3–4 nM for
SDF-1 binding to CXCR4 (27), protein kinase B activity
was stimulated 10-fold with 10 nM SDF-1 and maximum
activation (15–16-fold) was obtained with 100 nM SDF-1
at 1 min after stimulus addition (Fig. 4 B). At 20 min, pro-
tein kinase B activity was less pronounced (threefold acti-
vation) but a similar concentration dependence was ob-
served, suggesting that the receptor affinity does not change
during the course of activation and that the duration of the
agonist-induced response relies on the availability of SDF-1.
Western blot analysis of the kinase content in each immu-
noprecipitate revealed equal amounts of enzyme, exclud-
ing the possibility that different recoveries account for
the enhanced protein kinase B activities. Concentration-
dependent prolonged stimulation was also found for
ERK-2 (Fig. 4 C). At 1 mM SDF-1, activation was seen for
up to 2 h.
CXCR4 Downregulation. Activation of G protein–cou-
pled receptors generally results in rapid desensitization and
downregulation. To test if the prolonged stimulatory capac-
ity of CXCR4 is associated with reduced receptor internal-
ization, surface expression of CXCR4 was measured by
flow cytometry using PBMCs and the mAb 6H8. This anti-
body recognizes the NH2 terminus of CXCR4 and shows
only borderline interference (,5%) with ligand binding and
signal transduction (Thelen, M., and A. Amara, unpublished
data). Upon stimulation with SDF-1, surface expression of
CXCR4 is reduced in a concentration-dependent manner
(Fig. 5). Receptor downregulation is biphasic, with rapid
internalization during the first 5 min followed by a slower
phase lasting for up to 10 h. Receptor endocytosis was al-
ready observed at 1 nM SDF-1 but was more pronounced
with increasing agonist concentration. At 1 mM SDF-1, up
to 80% of the CXCR4 receptors were internalized within 5
min compared with 20% at 1 nM SDF-1. Similar rates of
internalization were found for other chemokine receptors,
e.g., CCR5 on PBLs stimulated with RANTES, and for
Figure 4. SDF-1 concentration dependence of prolonged protein ki-
nase B and ERK-2 activation. (A) Western blot analysis of protein kinase
B. T cells were stimulated with 10, 30, 100 nM or 1 mM SDF-1 for the
indicated times. Activated (pSer473 PKB) and total protein kinase B (PKB)
were determined as in the legend to Fig. 1 A. (B) Protein kinase B activ-
ity in immunoprecipitates from lysates of cells stimulated with the indi-
cated concentrations of SDF-1 for either 1 min (d) or 20 min (s). Re-
sults are expressed as fold activation. (C) Western blot analysis of ERK-2.
T cells were stimulated with 10, 100 nM and 1 mM SDF-1 for the indi-
cated times. Activated ERK-2 (pERK-2) corresponds to the band with
retarded electrophoretic mobility. Results are representative for at least
three independent determinations.319 Tilton et al.
CXCR4 in other cell types, such as T cell lines (Jurkat,
CEM) and HeLa. The observed biphasic internalization ki-
netics are not unique to CXCR4 and cannot be fundamen-
tal for the prolonged signaling in response to SDF-1. The
20% of receptors that remain at the cell surface may there-
fore be sufficient to continuously trigger downstream sig-
naling. This conclusion appears to contradict the signaling
properties shown above: higher concentrations of SDF-1
cause more pronounced CXCR4 internalization and con-
comitantly induce more sustained protein kinase B activa-
tion (Fig. 4) that depends on continuous CXCR4 surface
expression as shown with the receptor antagonist (Fig. 2).
To test the possible explanation that rapid receptor recy-
cling could account for the prolonged signaling capacity of
CXCR4, we incubated T cells with SDF-1 for different
times and after a brief acidic wash to remove bound and free
ligand (11) measured receptor reexpression in the presence
and absence of cycloheximide by flow cytometry. In agree-
ment with previous reports (11), only z20% of the initially
surface-expressed receptors recycled within 20 min (data
not shown), suggesting that receptor recycling may not be
the predominant mechanism for the prolonged signaling by
CXCR4, although not excluding it.
Restimulation of Protein Kinase B Activity with SDF-1.
As shown in Figs. 1 and 4, stimulation of T cells with
SDF-1 leads to an initial peak of protein kinase B activity
followed by a protracted phase that depends on the con-
centration of SDF-1. This observation suggests that the du-
ration of CXCR4 signaling may be limited by the avail-
ability of SDF-1 for receptor interaction. To test this
possibility, the cells were stimulated with 100 nM SDF-1
for different times and protein kinase B activity was deter-
mined in immunoprecipitates. In parallel incubations, a
second addition of 100 nM SDF-1 was made after 5, 20, or
60 min and protein kinase B activity was determined 1 min
later, i.e., at 6, 21, or 61 min. Unexpectedly for a G pro-
tein–coupled receptor, up to 80% of the maximum protein
kinase B activation could be recovered (Fig. 6 A). The ef-
fect was unique for SDF-1 stimulation of CXCR4. No en-
hancement of protein kinase B activity was obtained when
other chemokine receptors, e.g., CCR2 (MCP-1), were
restimulated, a finding that is in agreement with the general
notion that chemokine receptors are rapidly desensitized.
When intracellular calcium mobilization was measured,
CXCR4, as reported previously (32), was refractory to a
second stimulation with SDF-1 (Fig. 6 B). Desensitization
could be obtained in the presence of continuous recycling
of receptors. A peak of intracellular free calcium concentra-
tion requires a burst inositol 1,4,5-triphosphate formation
that triggers the sudden calcium release from intracellular
Figure 5. Downregulation of CXCR4 by SDF-1. PBMCs were incu-
bated in RPMI supplemented with 10% FCS without (control, 100% ex-
pression) or with increasing concentrations of SDF-1 for the times indi-
cated. Surface-expressed CXCR4 was detected with mAb 6H8 stained
with PE-conjugated goat anti–mouse IgG using a FACScan™ flow cy-
tometer. The percentage of CXCR4 surface expression was calculated
from the relative fluorescence intensity (see Materials and Methods). The
results shown are representative for four experiments obtained with cells
from different donors.
Figure 6. Restimulation of CXCR4 with SDF-1. (A) Protein kinase B
activation. T cells were stimulated with 100 nM SDF-1 for the indicated
times (points connected by solid line). In parallel samples, a second addi-
tion of 100 nM SDF-1 was made at 5, 20, or 60 min of stimulation (ar-
rowheads), and the incubation continued for 1 min (points connected by
thin line). The cells were lysed, and protein kinase B activity was mea-
sured in immunoprecipitates. Maximum protein kinase B activity ob-
tained at 1 min of stimulation was set as 100%. (B) Changes in intracellu-
lar free calcium. Fluorescence of Fura-2–loaded T cells was recorded for 6
min in parallel samples. At time 0 the cells were stimulated with 80 nM
SDF-1. Where indicated, 1 mM SDF-1P2G (P2G) was added 90 s later to
one sample (bottom trace), and at z280 s a second addition of 1 mM
SDF-1 (SDF-1) was made to both samples. (Inset) 1 mM SDF-1P2G
(P2G) does not desensitize the response to 1 mM SDF-1 (SDF-1). Results
are representative for at least three independent experiments performed in
duplicate with cells from different donors.320 CXCR4-mediated Signal Transduction
stores. Receptors that recycle to the cell surface would
stimulate a continuous IP3 formation, leading to moderate
cytosolic calcium fluxes that are counterbalanced by Ca-
ATPases. Thus, only marginal changes in intracellular free
calcium would be observed. In the experiment shown in
Fig. 6 B, parallel samples of Fura-2–loaded cells were stim-
ulated with 80 nM SDF-1, which induced a rapid rise in
intracellular free calcium. To one sample, a large excess of
SDF-1P2G (1 mM) was added 90 s later to displace bound
SDF-1 and to prevent binding of SDF-1 to potentially re-
cycling receptors. The antagonist does not stimulate a cal-
cium response per se (Fig. 6, inset). About 5 min after the
first addition of SDF-1, both samples were restimulated
with 1 mM SDF-1. Only a minimal response was observed
in both cases, suggesting that in the presence of SDF-1P2G
no receptors recycle to the cell surface that can be restimu-
lated with SDF-1. Taken together, the results shown in
Fig. 6 indicate that the CXCR4-mediated rise in cytosolic
free calcium is desensitized with a single dose of agonist,
whereas signaling leading to the activation of protein kinase
B can be restimulated.
Role of SDF-1 Degradation. Recent reports show that
the dipeptidyl dipeptidase IV CD26 cleaves several chemo-
kines near the NH2 terminus. Truncation of SDF-1 by
CD26 abolishes functional responses such as chemotaxis
and receptor internalization–dependent inhibition of HIV-1
infection (41). Because the availability of “active” (intact)
SDF-1 could be limiting for CXCR4-dependent signaling,
we tested the effect of the CD26 inhibitor, diprotin A, on
protein kinase B activation. Fig. 7 illustrates that the activa-
tion obtained with 30 nM SDF-1 lasting for up to 20 min
is prolonged up to 60 min in the presence of 4 mM dipro-
tin A, indicating that inactivation of SDF-1 by CD26 sig-
nificantly contributes to the termination of CXCR4-
dependent signaling. Similar effects of diprotin A were
observed when ERK-2 activation was measured. By contrast,
addition of diprotin A did not cause a detectable prolonga-
tion of protein kinase B or ERK-2 activation when MCP-1
or MIP-1b was used as stimulus.
Discussion
Chemokines can mediate diverse cellular processes such
as inflammatory responses, regulation of homing of lympho-
cytes, and embryogenesis. It is remarkable that chemokines
govern these responses by binding to related seven trans-
membrane domain receptors coupled to Gi proteins. In this
study, we investigated chemokine receptor–dependent sig-
nal transduction in human T cells to gain more information
on the initiation of the functional responses elicited by dif-
ferent chemokines. The results show that CXCR4 is dis-
tinct from other chemokine receptors by its capacity to
stimulate sustained activation of ERK-2, PI 3-kinase, and
protein kinase B, kinases that have been implicated in cell
proliferation, differentiation, and survival (42, 43). The
SDF-1–CXCR4 couple is involved in homeostasis rather
than inflammation, a notion that is supported by gene
knockout experiments which revealed that both SDF-1
and CXCR4 are required for embryogenesis (7–9). Thus,
it is conceivable that CXCR4 induces signal transduction
that leads to proliferation and differentiation. Several lines
of evidence suggest that PI 3-kinase–mediated activation of
protein kinase B inhibits apoptosis and promotes cell sur-
vival (22–24, 26, 44). Accordingly, sustained activation of
protein kinase B in the presence of SDF-1 could protect
CXCR4+ cells from undergoing apoptosis, a process that is
critical for the activation of T cells (45, 46).
The biochemical mechanisms responsible for the sus-
tained signaling by CXCR4 are not yet resolved. Gene dis-
ruption studies demonstrate that SDF-1 exclusively acts on
CXCR4 (7–9), and the finding that B. pertussis toxin blocks
the sustained signaling implies that initial coupling to a Gi
protein is essential. The unusual signaling characteristics of
CXCR4 are not restricted to specific cell types, as similar
responses were obtained with several hematopoietic cells
and with epithelium-derived HeLa cells. Our results dem-
onstrate that the prolonged signaling depends on continu-
ous receptor–agonist interaction at the cell surface, in
agreement with a model of reversible ligand–receptor in-
teraction as proposed for most G protein–coupled recep-
tors. The observation that displacement of SDF-1 by a re-
ceptor antagonist causes immediate termination of cellular
responses rules out the possibility that sustained signaling is
mediated by a “second wave of signaling” stimulated by
endocytosed or by sequestered and desensitized receptors
(47). However, it can be envisaged that an association with
adapter molecules preserves the receptor’s signaling capac-
ity and prevents its complete desensitization (47). This sec-
ond phase of signaling may not depend on coupling of the
receptor to heterotrimeric Gi proteins.
Rapid desensitization is a common hallmark of G pro-
tein–coupled receptors, leading to transient responses of
short duration. In fact, most chemokines that we tested on
T cells follow this scheme and induce only transient re-
sponses. Although RANTES at high concentrations can
stimulate a sustained calcium influx that depends on ty-
rosine phosphorylation (40), protein kinase B and ERK-2
activation is transient and rapidly desensitized (not shown).
These findings suggest that RANTES-mediated T cell acti-
vation is distinct from that induced by CXCR4. Desensiti-
zation is caused by receptor phosphorylation and is fol-
lowed by rapid receptor internalization. Changes in the
expression of selective chemokine receptors is a potential
Figure 7. Inhibition of CD26/
DPPIV (dipeptidyl dipeptidase
IV) prolongs SDF-1 stimulated
protein kinase B activation. T
cells were incubated with 30 nM
SDF-1 in the absence (Control)
or presence of 4 mM of the
CD26/DPPIV inhibitor dipro-
tin A for the indicated times. Ac-
tivated (pSer473PKB) and total
protein kinase B (PKB) were de-
termined by Western blot analy-
sis as in the legend to Fig. 1 A.321 Tilton et al.
mechanism by which the responsiveness of hematopoietic
cells is spatially and temporally coordinated (1, 5, 33). We
and others found no significant difference between SDF-1–
stimulated CXCR4 internalization and the internalization
rate of other chemokine receptors (11, 48, 49). Rapid re-
ceptor recycling can lead to the continuous surface expres-
sion of active receptors and could promote sustained signal-
ing. Reports by Amara et al. (11) and our own observations
indicate that only a small fraction of internalized receptors
(10–20%) recycle to the surface. However, this process is
relatively slow (20–40 min) and is not unique for CXCR4.
Calcium mobilization experiments as shown in Fig. 6 also
do not provide evidence for extensive receptor trafficking.
Thus, receptor recycling appears unlikely as the principal
mechanism for sustained signaling but cannot be com-
pletely ruled out.
Clearance of inducible chemokines is necessary to bal-
ance immune responses. In the case of the constitutively
expressed homing chemokines, elimination is a mandatory
mechanism to regulate their functions. Deregulated pro-
duction or degradation can have detrimental effects. CD26
participates in the process of T cell activation and when ex-
pressed on the surface of activated T cells, causes the inacti-
vation of several chemokines (41). In the present study, we
provide evidence that inhibition of CD26 results in pro-
longed SDF-1–induced signaling, suggesting that the
dipeptidyl peptidase inactivates SDF-1. Therefore, at sites
where it is highly expressed CD26 can attenuate CXCR4-
mediated responses, such as lymphopoiesis. On the other
hand, it has recently been reported that SDF-1 can bind
with high affinity to cell surface proteoglycans without in-
ducing cellular responses or interfering with SDF-1–
induced signaling through CXCR4 (50). This interaction
may lead to elevated local concentrations of active SDF-1.
Here, we show that high concentrations of SDF-1 or mul-
tiple additions of the chemokine induce sustained responses
in T cells (Figs. 4 and 6). However, the prolonged stimula-
tion of CXCR4 leads to complete downregulation of the
receptor (Fig. 5), suggesting that long-term exposure to
SDF-1 limits the responsiveness of CXCR4. Taken to-
gether, CD26 and slow receptor downregulation rather
than rapid desensitization determine the efficiency of SDF-
1–induced signaling.
Stimulation of PIP3 formation by G protein–coupled re-
ceptors is biphasic and involves two types of PI 3-kinases,
PI 3-kinaseg, which is activated by bg subunits of hetero-
trimeric G proteins (51), and a p85/p110 isoform, which is
activated by tyrosine kinase–regulated pathways (52). It was
suggested that the pronounced initial peak of PIP3 forma-
tion depends on PI 3-kinaseg (53), whereas a more pro-
tracted PIP3 formation is mediated by a p85/p110 isoform.
Because activation of protein kinase B reflects the kinetics
of PI 3-kinase stimulation, it is conceivable that the initial
prominent peak of protein kinase B activation is mediated
by the bg subunit–regulated PI 3-kinaseg, whereas the
more protracted activation is mediated by a p85/110 iso-
form (Fig. 1 B). Activation of the p85/110 isoform may be
mediated by binding of an adapter to the receptor and
could be independent of heterotrimeric G proteins (47).
Alternatively, the early peak of protein kinase B activity
could simply result from the simultaneous activation of a
large number of surface-expressed receptors that become
rapidly downregulated (Fig. 6).
Sustained activation has been shown to induce nuclear
translocation of both ERK-2 and protein kinase B (54–57).
In line with these reports, our preliminary experiments in-
dicate that stimulation with SDF-1 can lead to nuclear
translocation of both kinases (Ho, L., and M. Thelen,
manuscript in preparation). Whereas the role of ERK-2 as
activator of transcription is accepted (42), the nuclear trans-
location and possible gene activation by protein kinase B
are not well understood. An involvement of protein kinase
B in mRNA expression has been reported (58, 59), but the
mechanism remains elusive. In two recent reports, it was
shown that protein kinase B phosphorylates a nuclear fork-
head transcription factor that subsequently accumulates in
the cytosol (25, 26). Phosphorylation of this transcription
factor causes its inactivation and the downregulation of ap-
optosis-mediating genes such as Fas ligand (25). Thus, al-
though the role of protein kinase B in promoting cell sur-
vival is well documented, a general role of the kinase in
gene activation remains to be established.
We observed that ELC also stimulates a moderately pro-
longed response via CCR7. Like SDF-1 and CXCR4 that
are required for the engraftment of CD34+ cells (60) and
lymphopoiesis (9), ELC and CCR7 have been shown to be
important regulators of T cell homing and maturation (61–
63). It is plausible that chemokine receptors that mediate
hematopoiesis perform this function via induction of sus-
tained signals. Maturation of T cells may require the repet-
itive interaction with antigen-presenting cells (64). In this
respect, a stable source of SDF-1 could hold CXCR4+ cells
in place and concomitantly induce sustained activation of
mitogenic and survival pathways. The gradual loss of re-
sponsiveness to SDF-1 over 24 h would ensure that ma-
tured cells dissociate from antigen-presenting cells. Thus, it
is conceivable that CXCR4 is capable of providing costim-
ulatory signals in lymphocyte maturation.
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